Sagent Pharmaceuticals upgraded to Overweight from Neutral at Piper Jaffray Piper Jaffray upgraded Sagent Pharmaceuticals citing greater visibility following the company's Q4 results and raised its price target for shares to $22 from $15.
News For SGNT From The Last 14 Days
Check below for free stories on SGNT the last two weeks.
Sagent Pharmaceuticals to host a conference call Conference Call to discuss the agreement to acquire remaining 50% interest in its joint venture partner, Chengdu Kanghong Pharmaceuticals, as well as 1Q13 earnings, will be held on May 6 at 9 am. Webcast Link